Healthcare Equipment and Supplies
Company Overview of Akonni Biosystems, Inc.
Akonni Biosystems, Inc., a molecular diagnostics company, develops, manufactures, and markets integrated molecular diagnostic systems in the clinical market. It offers TruDiagnosis Systems, a platform that enables testing for various molecular markers associated with human diseases on a gel-drop microarray platform for clinical markets; and TruSentry system for government institutions and large centers to identify infectious microorganisms and drug resistant variants. The company provides Nucleic Acid Extraction Kits, which provides life science research and molecular laboratories with a means of extracting nucleic acids; and MDx Tests, which provides multiplexed molecular diagnostic analyse...
400 Sagner Avenue
Frederick, MD 21701
Founded in 2003
Key Executives for Akonni Biosystems, Inc.
Vice President of Operations
Director of Application Development
Compensation as of Fiscal Year 2014.
Akonni Biosystems, Inc. Key Developments
Akonni Biosystems, Inc. Expands Family of TruTip Extraction Products for Hamilton Microlab STAR Line of Liquid Ha
Jan 14 13
Akonni Biosystems, Inc. announced that it has extended its family of "smart-tip" extraction products for rapidly purifying human genomic deoxyribonucleic acid (gDNA) on the Hamilton Microlab(R) STAR(TM) line of robotic liquid handling workstations. The first product in the family of gDNA kits provides laboratory technicians with the ability to process up to 300 uL of fresh or frozen whole blood. This kit now has the added capability to be used to process other sample types including buffy coat, tissue, buccal swabs and cells. For all sample types, this kit delivers superior quality gDNA simultaneously from eight to 96 samples in less than 60 minutes. The second TruTip(R) gDNA kit now available supports the extraction and concentration of gDNA for up to 400 uL of saliva collected using Oragene(R) DISCOVER Collection Kit from DNA Genotek, Inc., a subsidiary of OraSure Technologies, Inc. Given the non-invasive nature of collecting gDNA from saliva samples compared to blood, this sample type is commonly used for very large-scale genetic studies, such as for breast cancer research. TruTip extraction kits running on Hamilton Microlab STAR system do not require a magnetic head, vacuum manifold, centrifuge, or other space-consuming or expensive capital equipment. Both TruTip gDNA Kits can be used with a variety of backend analytical tools, including qPCR, real time PCR, digital PCR, microarrays, and mid-multiplex bead-based systems, as well as traditional and next-generation sequencing systems.
Akonni Biosystems, Inc. Announces Pre-Clinical Results on Rapid, Low-Cost Array Moves Company Closer to Commercialization for its Infectious Disease Test Portfolio
Jan 8 13
Akonni Biosystems, Inc. announced results from three pre-clinical studies that contribute to the body of clinical evidence that verifies the efficacy of Akonni's TruDiagnosis molecular diagnostics (MDx) platform. Akonni TruArray(R) Tests are designed to fulfill market needs for mid-multiplex molecular diagnostics (tens to hundreds of molecular markers) deployed in near point-of-care settings, at a similar cost to conventional culture tests and with the accuracy and speed of gold-standard low-multiplex approaches. These studies, including those for methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Mycobacterium tuberculosis (MDR-TB), and influenza subtyping, were funded and developed over the past six years by carefully leveraging more than $45 million in private and public funding from the National Institutes of Health (NIH), Centers for Disease Control (CDC), National Science Foundation (NSF), and the Department of Defense (DOD). The aggregate market opportunity for infectious disease diagnostics exceeds $3 billion in the United States alone, according to report by Cowen & Company, LLC. Akonni's TruDiagnosis platform is positioned to exploit this and broader global health markets with its unique TruArray Tests, which are designed to significantly reduce the complexity and cost of traditional mid-multiplex microarray consumables, equipment, and workflows for laboratory technicians. Mid-level multiplexed molecular assays that can be deployed in the field or in lower-resource settings are particularly useful for infectious disease diagnostics, detecting drug resistance markers, and improving the health of at-risk populations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|